Evidence map›Paper›PMID 29296534›Full record

ArticleOncoimmunology

Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy.

Lisa König, Sabine Kasimir-Bauer, Ann-Kathrin Bittner, Oliver Hoffmann, Bettina Wagner, Luis Felipe Santos Manvailer, Rainer Kimmig, Peter A Horn, Vera Rebmann

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Enter sandman: how to tackle dormant breast cancer cells.Medical oncology (Northwood, London, England) · 2025
    Review
  12. Review
  13. Article
  14. Harnessing extracellular vesicle-mediated crosstalk between T cells and cancer cells for therapeutic applications.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  15. A single-sEV analysis identifies plasma EPCAMExtracellular vesicles and circulating nucleic acids · 2025
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Lisa KönigInstitute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Sabine Kasimir-BauerDepartment of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Ann-Kathrin BittnerDepartment of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Oliver HoffmannDepartment of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Bettina WagnerInstitute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Luis Felipe Santos ManvailerInstitute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Rainer KimmigDepartment of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Peter A HornInstitute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Vera RebmannInstitute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
University of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) have been discussed as a diagnostic tool for minimal residual disease (MRD) evaluation in breast cancer (BC) in addition to the analysis of circulating tumor cells (CTCs). Therefore, we investigated circulating EV levels as surrogate markers for disease monitoring and prediction of prognosis in primary, non-metastatic, locally advanced BC patients. EVs were enriched from blood samples of BC patients before and after neoadjuvant chemotherapy (NACT) and from healthy females. EV marker expression analysis was performed and EV sizes and concentrations were determined by nanoparticle tracking analysis. The results were associated with disease status, outcome and CTC presence, evaluated by gene expression analysis after enrichment. We demonstrated that i) the EV concentration was 40-fold higher in BC patients compared to healthy females, ii) the EV concentration increased during therapy, iii) an increased EV concentration pre-NACT was associated with therapy failure and iv) an elevated EV concentration post-NACT was associated with a reduced three-year progression-free and overall survival. Of note, residual stem cell-like and/or resistant CTCs after therapy were associated with a lower EV concentration post-NACT. Our study highlights that the concentration of EVs within BC blood samples may serve as a complementary parameter reflecting the status of MRD as well as therapy and disease outcome in parallel with CTC investigation.

Indexed as

Breast Cancercirculating tumor cellsextracellular vesiclesminimal residual diseaseneoadjuvant chemotherapy

Identifiers

PMID29296534
PMCPMC5739576
OpenAlexW2751524450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.